Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology.

The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer.

This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. BioMark is proud to highlight that the work led by Dr. Vaida has been recognized for its high quality and its significant contribution to the field of oncology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.

"The acceptance of our work in Frontiers in Oncology is a pivotal moment for BioMark, as it provides third-party validation of the investments we have made in AI and machine learning over the past several years," said Rashid Ahmed Bux, President and CEO of BioMark. "At a time when the healthcare industry is increasingly looking for 'proof of concept' in AI applications, this publication confirms that our collaborative work with Harrisburg University meets the highest standards of scientific excellence. We have successfully demonstrated that integrating machine learning with metabolomics is not just a theoretical pursuit, but a validated methodology that provides deep insights into the metabolic complexities of lung cancer."

The full paper is expected to be published later this month and will be made available through BioMark's website. This milestone reinforces the company's commitment to scientific transparency and its position at the intersection of oncology, metabolomics, and advanced data science.

About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark Diagnostics Inc. is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

Further information about BioMark Diagnostic Inc. is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com.

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark Diagnostics Inc. Forward-Looking information is based on certain key expectations and assumptions made by the management of the company. Although it believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark Diagnostics Inc. can give no assurance that they will prove to be correct. Forward-Looking statements contained in this press release are made as of the date of this press release. BioMark Diagnostics Inc. disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved of the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280406